Cilostazol: Difference between revisions
m Adding Chemspider ID |
Clarified intro and added Mechanism section. In mechanism, added cAMP/PKA/platelet-aggregation relationship. |
||
| Line 29: | Line 29: | ||
Although drugs similar to cilostazol have increased the risk of death in patients with [[congestive heart failure]], studies of significant size have not addressed people without the disease. |
Although drugs similar to cilostazol have increased the risk of death in patients with [[congestive heart failure]], studies of significant size have not addressed people without the disease. |
||
Cilostazol is a selective [[ |
Cilostazol is a selective [[phosphodiesterase|PDE3]] [[phosphodiesterase inhibitor]] with therapeutic focus on [[Cyclic adenosine monophosphate|cAMP]]. It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the [[artery|arteries]] supplying [[blood]] to the legs and decreasing [[platelet]] [[coagulation]]. |
||
== |
==Mechanism== |
||
Cilostazol is a selective [[phosphodiesterase|PDE3]] [[phosphodiesterase inhibitor]] with therapeutic focus on increasing [[Cyclic adenosine monophosphate|cAMP]]. An increase in cAMP results in an increase in [[Protein kinase A|PKA]], which is directly related with an inhibition in platelet aggregation. |
|||
==Clinical Use== |
|||
Cilostazol is approved for the treatment of [[intermittent claudication]]. The typical dose is 100 [[milligram|mg]] twice a day. The effects may take as much as 3 months to be evident. |
Cilostazol is approved for the treatment of [[intermittent claudication]]. The typical dose is 100 [[milligram|mg]] twice a day. The effects may take as much as 3 months to be evident. |
||
Revision as of 08:29, 6 March 2009
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 95–98% |
| Metabolism | Hepatic (CYP3A4- and CYP2C19-mediated) |
| Elimination half-life | 11–13 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.215.897 |
| Chemical and physical data | |
| Formula | C20H27N5O2 |
| Molar mass | 369.46 g/mol g·mol−1 |
Cilostazol (Template:PronEng) is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal.
Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease.
Cilostazol is a selective PDE3 phosphodiesterase inhibitor with therapeutic focus on cAMP. It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation.
Mechanism
Cilostazol is a selective PDE3 phosphodiesterase inhibitor with therapeutic focus on increasing cAMP. An increase in cAMP results in an increase in PKA, which is directly related with an inhibition in platelet aggregation.
Clinical Use
Cilostazol is approved for the treatment of intermittent claudication. The typical dose is 100 mg twice a day. The effects may take as much as 3 months to be evident.
In people with heart failure
Cilostazol, clearly effective for a debilitating condition whose current treatment is often inadequate, is a member of a pharmacologic class that is dangerous to people with severe heart failure and unstudied in other people. Cilostazol has been studied in people without heart failure, without evidence of harm, but much more data would be needed to determine that there is no risk at all. Although cilostazol would not be approvable for a trivial condition the Cardio-Renal Advisory Committee and FDA concluded that fully informed patients and physicians should be able to choose to use it to treat intermittent claudication. Patient and physician labeling will describe the basis for concern and the incomplete information available.[2]
Adverse effects
Possible side effects of cilostazol use include headache (the most common), diarrhea, abnormal stools, increased heart rate, and palpitations.[3]
Interactions
Cilostazol is metabolized by CYP3A4 and CYP2C19, two isoenzymes of the cytochrome P450 system. Drugs that inhibit CYP3A4, such as itraconazole, erythromycin, ketoconazole, and diltiazem, are known to interact with cilostazol. The proton pump inhibitor omeprazole, a potent inhibitor of CYP2C19, increases exposure to the active metabolite of cilostazol.[3]
There has been a single report of grapefruit juice possibly increasing the effects of cilostazol;[4] some drug information sources list this as a possible interaction.[5][6][7] The FDA-approved labeling of cilostazol notes that grapefruit juice (which is a CYP3A4 inhibitor) increases the drug's maximum concentration by around 50%.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Center for Drug Evaluation and Research (August 11 1999). "Approval of Cilostazol". U.S. Food and Drug Administration. Retrieved 2007-04-30.
{{cite web}}: Check date values in:|date=(help) - ^ a b c "Cilostazol: Official FDA information, side effects and uses". Drugs.com. February 2008. Retrieved 2008-09-22.
- ^ Taniguchi K, Ohtani H, Ikemoto T, Miki A, Hori S, Sawada Y (2007). "Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice". J Clin Pharm Ther. 32 (5): 457–9. doi:10.1111/j.1365-2710.2007.00844.x. PMID 17875111.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ "Cilostazol for peripheral arterial disease". Yahoo! Health. Retrieved 2008-09-21.
- ^ "Cilostazol". MedicineNet.com. May 25, 1999. Retrieved 2008-09-22.
- ^ Cerner-Multum, Inc. (November 29, 2007). "Consumer Drug Information: Cilostazol". Drugs.com. Retrieved 2008-09-22.